Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the overall response rate to erlotinib in
patients with polycythemia vera (PV). Response rate will be assessed by improvement in the
complete blood count, ultrasound of the spleen, and JAK2 molecular status. It is purposed in
this study to explore a possible molecular targeting of the driving mechanism of PV.